OBJECTIVE: Preeclampsia (PE) is diagnosed using clinical criteria and in atypical cases the diagnosis may be inaccurate as there are no specific tests to confirm or exclude PE. This study sought to evaluate the utility of angiogenic biomarkers, sFlt1, sEng and PlGF to distinguish patients with gestational thrombocytopenia and immune thrombocytopenic purpura (ITP) from patients with thrombocytopenia resulting from the HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome, a complication of severe PE. METHODS: Serum was collected and the angiogenic biomarkers of patients with ITP and gestational thrombocytopenia (N = 9) were compared to patients with HELLP (N = 11) and PE (N = 11). Circulating levels of these angiogenic biomarkers were also compared by gestational age to 1564 randomly selected normotensive women from the Calcium for Preeclampsia Prevention study. RESULTS: Patients with non-HELLP thrombocytopenia had lower sFlt1 (7.3 +/- 3.8 ng/ml vs. 15.5 +/- 5 ng/ml, P < 0.001), lower sEng (8.7 +/- 3.6 vs. 34 +/- 17, P < 0.001) and higher PlGF (484 +/- 412 vs. 66.3 +/- 44, P = 0.003) than patients with HELLP syndrome. Angiogenic factor abnormalities in patients with PE were similar to patients with HELLP syndrome, suggesting a common pathogenesis. Patients with non-HELLP thrombocytopenia had angiogenic profiles similar to normotensive controls, whereas patients with HELLP syndrome had levels higher than the 90th percentile for sFlt1 and sEng and lower than the 10th percentile for PlGF. CONCLUSIONS: Angiogenic biomarkers may be useful in excluding conditions that mimic PE.
OBJECTIVE:Preeclampsia (PE) is diagnosed using clinical criteria and in atypical cases the diagnosis may be inaccurate as there are no specific tests to confirm or exclude PE. This study sought to evaluate the utility of angiogenic biomarkers, sFlt1, sEng and PlGF to distinguish patients with gestational thrombocytopenia and immune thrombocytopenic purpura (ITP) from patients with thrombocytopenia resulting from the HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome, a complication of severe PE. METHODS: Serum was collected and the angiogenic biomarkers of patients with ITP and gestational thrombocytopenia (N = 9) were compared to patients with HELLP (N = 11) and PE (N = 11). Circulating levels of these angiogenic biomarkers were also compared by gestational age to 1564 randomly selected normotensive women from the Calcium for Preeclampsia Prevention study. RESULTS:Patients with non-HELLP thrombocytopenia had lower sFlt1 (7.3 +/- 3.8 ng/ml vs. 15.5 +/- 5 ng/ml, P < 0.001), lower sEng (8.7 +/- 3.6 vs. 34 +/- 17, P < 0.001) and higher PlGF (484 +/- 412 vs. 66.3 +/- 44, P = 0.003) than patients with HELLP syndrome. Angiogenic factor abnormalities in patients with PE were similar to patients with HELLP syndrome, suggesting a common pathogenesis. Patients with non-HELLP thrombocytopenia had angiogenic profiles similar to normotensive controls, whereas patients with HELLP syndrome had levels higher than the 90th percentile for sFlt1 and sEng and lower than the 10th percentile for PlGF. CONCLUSIONS: Angiogenic biomarkers may be useful in excluding conditions that mimic PE.
Authors: J C Hauth; M G Ewell; R J Levine; J R Esterlitz; B Sibai; L B Curet; P M Catalano; C D Morris Journal: Obstet Gynecol Date: 2000-01 Impact factor: 7.661
Authors: R J Levine; J C Hauth; L B Curet; B M Sibai; P M Catalano; C D Morris; R DerSimonian; J R Esterlitz; E G Raymond; D E Bild; J D Clemens; J A Cutler Journal: N Engl J Med Date: 1997-07-10 Impact factor: 91.245
Authors: Eiji Shibata; Augustine Rajakumar; Robert W Powers; Robert W Larkin; Carol Gilmour; Lisa M Bodnar; William R Crombleholme; Roberta B Ness; James M Roberts; Carl A Hubel Journal: J Clin Endocrinol Metab Date: 2005-05-10 Impact factor: 5.958
Authors: Tinnakorn Chaiworapongsa; Roberto Romero; Yeon Mee Kim; Gi Jin Kim; Mi Ran Kim; Jimmy Espinoza; Emmanuel Bujold; Luís Gonçalves; Ricardo Gomez; Samuel Edwin; Moshe Mazor Journal: J Matern Fetal Neonatal Med Date: 2005-01
Authors: Richard J Levine; Ravi Thadhani; Cong Qian; Chun Lam; Kee-Hak Lim; Kai F Yu; Anastasia L Blink; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi Journal: JAMA Date: 2005-01-05 Impact factor: 56.272
Authors: Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi Journal: N Engl J Med Date: 2004-02-05 Impact factor: 91.245
Authors: Bruno M Polliotti; A Gordon Fry; Devereux N Saller; Robert A Mooney; Christopher Cox; Richard K Miller Journal: Obstet Gynecol Date: 2003-06 Impact factor: 7.661
Authors: Stacy Zamudio; Marcus Borges; Lourdes Echalar; Olga Kovalenko; Enrique Vargas; Tatiana Torricos; Abdulla Al Khan; Manuel Alvarez; Nicholas P Illsley Journal: Biol Reprod Date: 2014-02-27 Impact factor: 4.285